

Julia C Stingl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3145571/publications.pdf>

Version: 2024-02-01

233
papers

13,949
citations

24978

57
h-index

24179

110
g-index

253
all docs

253
docs citations

253
times ranked

13020
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodelling affecting orthodontic treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 132-140. | 1.2 | 2 |
| 2 | Classification of Companion Diagnostics: A New Framework for Biomarker-Driven Patient Selection. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 244-254. | 0.8 | 3 |
| 3 | Association of <i>CYP2B6</i> genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2022, 42, 34-44. | 1.2 | 5 |
| 4 | Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes. <i>Pharmacogenomics Journal</i> , 2022, , . | 0.9 | 0 |
| 5 | Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle. <i>BJPsych Open</i> , 2022, 8, e20. | 0.3 | 4 |
| 6 | Green Tea Extract to Prevent Colorectal Adenomas, Results of a Randomized, Placebo-Controlled Clinical Trial. <i>American Journal of Gastroenterology</i> , 2022, 117, 884-894. | 0.2 | 18 |
| 7 | Catch Me if You Can: the Crosstalk of Zika Virus and the Restriction Factor Tetherin. <i>Journal of Virology</i> , 2022, 96, jvi0211721. | 1.5 | 1 |
| 8 | Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 173-182. | 0.7 | 10 |
| 9 | Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera. <i>Viruses</i> , 2022, 14, 410. | 1.5 | 3 |
| 10 | Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 565-570. | 3.0 | 17 |
| 11 | Polypharmacy, potentially inappropriate medication and pharmacogenomics drug exposure in the Rhineland Study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2732-2756. | 1.1 | 8 |
| 12 | Targeting Cholesterol Metabolism as Efficient Antiviral Strategy Against the Hepatitis E Virus. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 159-180. | 2.3 | 20 |
| 13 | Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. <i>PLoS ONE</i> , 2021, 16, e0247446. | 1.1 | 14 |
| 14 | Clinically relevant enantiomer specific and praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00769. | 1.1 | 5 |
| 15 | Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110228. | 2.5 | 18 |
| 16 | Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity. <i>Oncotarget</i> , 2021, 12, 982-995. | 0.8 | 0 |
| 17 | CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 624104. | 1.6 | 6 |
| 18 | Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) <i>Trends in Psychiatry</i> , 2021, 22, 561-628. | 1.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populationsâ€”Implication for Drug Safety, Dosing, and Individualized Therapy. <i>Frontiers in Genetics</i> , 2021, 12, 692234. | 1.1 | 35 |
| 20 | Hypoglycemia in Older Adults: Time Trends and Treatment Differences in Patients Aged â‰¥75 Years With Type 2 Diabetes. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 1898-1905.e1. | 1.2 | 5 |
| 21 | Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain. <i>Translational Psychiatry</i> , 2021, 11, 467. | 2.4 | 7 |
| 22 | Fall-Associated Drugs in Community-Dwelling Older Adults: Results from the ActiFE Ulm Study. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2177-2183.e10. | 1.2 | 1 |
| 23 | Translational pharmacogenetics: pharmacogenetically driven clinical decision making. , 2021, , 71-83. | | 0 |
| 24 | Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs. <i>BMC Pharmacology & Toxicology</i> , 2021, 22, 56. | 1.0 | 6 |
| 25 | Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)â€”Never Change a Running System?. <i>Pharmaceuticals</i> , 2021, 14, 1056. | 1.7 | 0 |
| 26 | Analysis of BNT162b2â€™and CVnCoVâ€™elicited sera and of convalescent sera toward SARSâ€™CoVâ€™2 viruses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, , . | 2.7 | 9 |
| 27 | Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes. <i>Vaccines</i> , 2021, 9, 1419. | 2.1 | 4 |
| 28 | Prevalence of ABCB1 3435C>T polymorphism in the Cuban population. <i>Drug Metabolism and Personalized Therapy</i> , 2021, . | 0.3 | 0 |
| 29 | Validation of selfâ€™reported medication use applying untargeted mass spectrometryâ€™based metabolomics techniques in the Rhineland study. <i>British Journal of Clinical Pharmacology</i> , 2021, , . | 1.1 | 3 |
| 30 | P.429 Painful choices â€” an fMRI study using a decision-making paradigm to investigate the appraisal of suffering in others. <i>European Neuropsychopharmacology</i> , 2020, 40, S243-S244. | 0.3 | 0 |
| 31 | Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity. <i>Translational Psychiatry</i> , 2020, 10, 338. | 2.4 | 10 |
| 32 | Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. <i>BMJ Open</i> , 2020, 10, e032624. | 0.8 | 1 |
| 33 | Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144. | 0.7 | 26 |
| 34 | Impact of Zika Virus Infection on Human Neural Stem Cell MicroRNA Signatures. <i>Viruses</i> , 2020, 12, 1219. | 1.5 | 19 |
| 35 | The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2144-2154. | 1.1 | 14 |
| 36 | Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?â€”Results from the ADRED Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1801. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. <i>Pharmacogenomics Journal</i> , 2020, 20, 840-844. | 0.9 | 2 |
| 38 | Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. <i>PLoS ONE</i> , 2020, 15, e0230632. | 1.1 | 8 |
| 39 | Citalopram-induced pathways regulation and tentative treatment-outcome-predicting biomarkers in lymphoblastoid cell lines from depression patients. <i>Translational Psychiatry</i> , 2020, 10, 210. | 2.4 | 7 |
| 40 | Prevalence of Psychotropic Drugs in Cases of Severe Adverse Drug Reactions Leading to Unplanned Emergency Visits in General Hospitals. <i>Pharmacopsychiatry</i> , 2020, 53, 133-137. | 1.7 | 6 |
| 41 | Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 439-448. | 0.8 | 15 |
| 42 | Pregnancy exposure to venlafaxine—Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. <i>Journal of Affective Disorders</i> , 2020, 266, 578-584. | 2.0 | 10 |
| 43 | Signals of anticipation of reward and of mean reward rates in the human brain. <i>Scientific Reports</i> , 2020, 10, 4287. | 1.6 | 6 |
| 44 | The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 431-440. | 1.5 | 31 |
| 45 | Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 25. | 1.0 | 23 |
| 46 | Healthcare Professionals' Knowledge of Pharmacogenetics and Attitudes Towards Antimicrobial Utilization in Zambia: Implications for a Precision Medicine Approach to Reducing Antimicrobial Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 551522. | 1.6 | 7 |
| 47 | Green tea extract to prevent colorectal adenomas in men and women: Results of the MIRACLE trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1551-1551. | 0.8 | 0 |
| 48 | Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 313-316. | 2.3 | 14 |
| 49 | Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , 2019, 20, 643-657. | 0.6 | 65 |
| 50 | MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: A randomized, controlled trial. <i>Annals of Oncology</i> , 2019, 30, v869. | 0.6 | 2 |
| 51 | Drug-induced anaphylactic reactions in children: A retrospective analysis of 159 validated spontaneous reports. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 377-388. | 0.9 | 11 |
| 52 | Companion Diagnostics and Biomarker Tests in the European Medicines Agency's Assessment of Medicinal Products. , 2019, , 319-333. | | 3 |
| 53 | Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. <i>Diabetes Care</i> , 2019, 42, 1027-1033. | 4.3 | 43 |
| 54 | Interferon-beta-induced changes in neuroimaging phenotypes of appetitive motivation and reactivity to emotional salience. <i>NeuroImage: Clinical</i> , 2019, 24, 102020. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45. | 1.4 | 27 |
| 56 | Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. <i>Clinical Pharmacokinetics</i> , 2019, 58, 535-543. | 1.6 | 20 |
| 57 | Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms. <i>Frontiers in Pharmacology</i> , 2019, 10, 1620. | 1.6 | 3 |
| 58 | TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 162-174. | 1.3 | 103 |
| 59 | Mindful Pharmacogenetics: Drug Dosing for Mental Health. <i>American Journal of Psychiatry</i> , 2018, 175, 395-397. | 4.0 | 5 |
| 60 | Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62. | 1.7 | 787 |
| 61 | Repeated fMRI in measuring the activation of the amygdala without habituation when viewing faces displaying negative emotions. <i>PLoS ONE</i> , 2018, 13, e0198244. | 1.1 | 13 |
| 62 | Diagnosis of Li-Fraumeni Syndrome: Differentiating <i>TP53</i> germline mutations from clonal hematopoiesis. <i>Human Mutation</i> , 2018, 39, 2040-2046. | 1.1 | 20 |
| 63 | Accelerated 3D ² GRASE imaging improves quantitative multiple post labeling delay arterial spin labeling. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2475-2484. | 1.9 | 23 |
| 64 | Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65. | 1.3 | 38 |
| 65 | Potential Drug-Drug Interactions in a Cohort of Elderly, Polymedicated Primary Care Patients on Antithrombotic Treatment. <i>Drugs and Aging</i> , 2018, 35, 559-568. | 1.3 | 16 |
| 66 | The neural correlates of decisions about sadness in facial expressions.. <i>Journal of Neuroscience, Psychology, and Economics</i> , 2018, 11, 93-105. | 0.4 | 6 |
| 67 | Population nutrkinetics of green tea extract. <i>PLoS ONE</i> , 2018, 13, e0193074. | 1.1 | 51 |
| 68 | Adverse Drug Reactions (ADR) and Emergencies. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 251-258. | 0.6 | 55 |
| 69 | Frequent Adverse Drug Reactions, and Medication Groups under Suspicion. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 393-400. | 0.6 | 27 |
| 70 | Pharmacogenomics and Precision Psychiatry. , 2018, , 96-102. | | 0 |
| 71 | In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 594-595. | 0.6 | 0 |
| 72 | Multimodal FLAIR/MPRAGE segmentation of cerebral cortex and cortical myelin. <i>NeuroImage</i> , 2017, 152, 130-141. | 2.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The iconography of mourning and its neural correlates: a functional neuroimaging study. <i>Social Cognitive and Affective Neuroscience</i> , 2017, 12, 1303-1313. | 1.5 | 17 |
| 74 | Influence of caffeine and paraxanthine on structural magnetic resonance imaging. <i>European Neuropsychopharmacology</i> , 2017, 27, S3-S4. | 0.3 | 0 |
| 75 | Multimorbidity, polypharmacy and pharmacogenomics in old age. <i>Pharmacogenomics</i> , 2017, 18, 515-517. | 0.6 | 17 |
| 76 | Gene expression and proliferation biomarkers for antidepressant treatment resistance. <i>Translational Psychiatry</i> , 2017, 7, e1061-e1061. | 2.4 | 22 |
| 77 | Clinical pharmacogenetics implementation consortium guideline (CPIC) for <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and dosing of tricyclic antidepressants: 2016 update. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 37-44. | 2.3 | 450 |
| 78 | Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358. | 2.3 | 240 |
| 79 | Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics. <i>Pharmacogenomics</i> , 2017, 18, 1281-1297. | 0.6 | 19 |
| 80 | Metabolite profiling in identifying metabolic biomarkers in older people with late-onset type 2 diabetes mellitus. <i>Scientific Reports</i> , 2017, 7, 4392. | 1.6 | 34 |
| 81 | Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 213-219. | 2.5 | 22 |
| 82 | Medical education in pharmacogenomics – results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1247-1252. | 0.8 | 73 |
| 83 | Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting. <i>Psychiatry Research - Neuroimaging</i> , 2017, 259, 16-24. | 0.9 | 9 |
| 84 | Multimodal MEMPRAGE, FLAIR, and R2* Segmentation to Resolve Dura and Vessels from Cortical Gray Matter. <i>Frontiers in Neuroscience</i> , 2017, 11, 258. | 1.4 | 23 |
| 85 | A Computerized Version of the Scrambled Sentences Test. <i>Frontiers in Psychology</i> , 2017, 8, 2310. | 1.1 | 12 |
| 86 | Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017, 8, 35193-35204. | 0.8 | 10 |
| 87 | Objectively Measured Walking Duration and Sedentary Behaviour and Four-Year Mortality in Older People. <i>PLoS ONE</i> , 2016, 11, e0153779. | 1.1 | 49 |
| 88 | S1 – Leitlinie zur Diagnostik und Therapie der Skabies – Kurzfassung. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1160-1171. | 0.4 | 17 |
| 89 | Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016, 55, 131-139. | 1.3 | 19 |
| 90 | S1 guidelines on the diagnosis and treatment of scabies – short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1155-1167. | 0.4 | 88 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Proliferation rates and gene expression profiles in human lymphoblastoid cell lines from patients with depression characterized in response to antidepressant drug therapy. <i>Translational Psychiatry</i> , 2016, 6, e950-e950. | 2.4 | 15 |
| 92 | Pharmacogenetic biomarkers for companion and complementary diagnostics: challenges for clinical practice and regulation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 415-418. | 0.4 | 0 |
| 93 | Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. <i>BMC Family Practice</i> , 2016, 17, 49. | 2.9 | 14 |
| 94 | CYP450 genotype and pharmacogenetic association studies: a critical appraisal. <i>Pharmacogenomics</i> , 2016, 17, 259-275. | 0.6 | 38 |
| 95 | The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>Journal of Psychopharmacology</i> , 2016, 30, 40-47. | 2.0 | 34 |
| 96 | High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: A multicenter cohort study on 215,932 patients from the German/Austrian diabetes registry. <i>Diabetes Research and Clinical Practice</i> , 2016, 112, 73-81. | 1.1 | 37 |
| 97 | Serum Vitamin D Concentrations and Cognitive Function in a Population-Based Study among Older Adults in South Germany. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1119-1126. | 1.2 | 22 |
| 98 | Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 25. | 1.0 | 6 |
| 99 | Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1219-1232. | 1.5 | 33 |
| 100 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 127-134. | 2.3 | 739 |
| 101 | Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. <i>Journal of Internal Medicine</i> , 2015, 277, 167-177. | 2.7 | 56 |
| 102 | CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. <i>Pharmacogenomics</i> , 2015, 16, 689-701. | 0.6 | 22 |
| 103 | Individual variability in the Pharmacokinetic of Tea Polyphenols and gene expression after oral intake of Green Tea extract. <i>Clinical Therapeutics</i> , 2015, 37, e116. | 1.1 | 2 |
| 104 | Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015, 136, 94-100. | 0.8 | 2 |
| 105 | Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548. | 0.9 | 34 |
| 106 | The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. <i>Translational Psychiatry</i> , 2015, 5, e553-e553. | 2.4 | 107 |
| 107 | Translational Pharmacogenetics to Support Pharmacogenetically Driven Clinical Decision Making. , 2015, , 59-73. | | 0 |
| 108 | High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 1605-1619. | 0.6 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.. Journal of Clinical Oncology, 2015, 33, TPS786-TPS786. | 0.8 | 1 |
| 110 | Physical Activity and Different Concepts of Fall Risk Estimation in Older Peopleâ€“Results of the ActiFE-Ulm Study. PLoS ONE, 2015, 10, e0129098. | 1.1 | 73 |
| 111 | Where Failure Is Not an Option â€“Personalized Medicine in Astronauts. PLoS ONE, 2015, 10, e0140764. | 1.1 | 29 |
| 112 | Gene regulatory biomarker identification for skin toxicities induced by EGFR inhibitor treatment. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 1056-1058. | 0.3 | 1 |
| 113 | Neural Activation in Humans during a Simple Motor Task Differs between BDNF Polymorphisms. PLoS ONE, 2014, 9, e96722. | 1.1 | 8 |
| 114 | Use of magnetic resonance imaging in pharmacogenomics. British Journal of Clinical Pharmacology, 2014, 77, 684-694. | 1.1 | 8 |
| 115 | Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. , 2014, 141, 92-116. | | 151 |
| 116 | Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. European Journal of Cancer, 2014, 50, 1855-1863. | 1.3 | 46 |
| 117 | CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. Clinical Pharmacology and Therapeutics, 2014, 95, 216-227. | 2.3 | 150 |
| 118 | Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model. Clinical Pharmacokinetics, 2013, 52, 359-371. | 1.6 | 5 |
| 119 | Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochemical Pharmacology, 2013, 86, 666-678. | 2.0 | 168 |
| 120 | Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. Pharmacogenomics Journal, 2013, 13, 181-188. | 0.9 | 29 |
| 121 | Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Molecular Psychiatry, 2013, 18, 273-287. | 4.1 | 154 |
| 122 | Depression with psychotic features is influenced by the polymorphism of the serotonin transporter gene. Journal of Affective Disorders, 2013, 151, 605-610. | 2.0 | 9 |
| 123 | Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. Clinical Pharmacology and Therapeutics, 2013, 93, 402-408. | 2.3 | 397 |
| 124 | Routine Micromethod for the Determination of Vitamin K1 in Human Plasma. Therapeutic Drug Monitoring, 2013, 35, 859-862. | 1.0 | 5 |
| 125 | Study Designs in Clinical Pharmacogenetic and Pharmacogenomic Research. , 2013, , 309-341. | | 2 |
| 126 | Association of objectively measured physical activity with established and novel cardiovascular biomarkers in elderly subjects: every step counts. Journal of Epidemiology and Community Health, 2013, 67, 194-197. | 2.0 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Neural Correlates of Erotic Stimulation under Different Levels of Female Sexual Hormones. PLoS ONE, 2013, 8, e54447. | 1.1 | 64 |
| 128 | Therapeutic Drug Monitoring of Children and Adolescents Treated with Fluoxetine. Pharmacopsychiatry, 2012, 45, 72-76. | 1.7 | 25 |
| 129 | Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics, 2012, 13, 1129-1139. | 0.6 | 57 |
| 130 | HLA polymorphisms influence the development of skin rash arising from treatment with EGF receptor inhibitors. Pharmacogenomics, 2012, 13, 1469-1476. | 0.6 | 9 |
| 131 | Genetic variants in PSEN2 and correlation to CSF β -amyloid42 levels in AD. Neurobiology of Aging, 2012, 33, 201.e9-201.e18. | 1.5 | 6 |
| 132 | Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics, 2012, 13, 1405-1417. | 0.6 | 17 |
| 133 | Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. NeuroImage, 2012, 59, 2818-2823. | 2.1 | 30 |
| 134 | Effect of paroxetine and bupropion on human resting brain perfusion: An arterial spin labeling study. NeuroImage, 2012, 61, 773-779. | 2.1 | 19 |
| 135 | An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. Journal of Thrombosis and Haemostasis, 2012, 10, 767-772. | 1.9 | 15 |
| 136 | Prevalence and comorbidity of chronic pain in the German general population. Journal of Psychiatric Research, 2012, 46, 444-450. | 1.5 | 94 |
| 137 | The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population. Journal of Clinical Oncology, 2012, 30, TPS1612-TPS1612. | 0.8 | 0 |
| 138 | Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion. Neuropsychopharmacology, 2011, 36, 1837-1847. | 2.8 | 77 |
| 139 | Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. Breast Cancer Research, 2011, 13, R57. | 2.2 | 38 |
| 140 | CYP2D6 in the Brain: Impact on Suicidality. Clinical Pharmacology and Therapeutics, 2011, 89, 352-353. | 2.3 | 35 |
| 141 | Why, When, and How Should Pharmacogenetics Be Applied in Clinical Studies?: Current and Future Approaches to Study Designs. Clinical Pharmacology and Therapeutics, 2011, 89, 198-209. | 2.3 | 39 |
| 142 | Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol. Clinical Pharmacology and Therapeutics, 2011, 90, 143-150. | 2.3 | 126 |
| 143 | CYP2D6 in the brain: genotype effects on resting brain perfusion. Molecular Psychiatry, 2011, 16, 333-341. | 4.1 | 49 |
| 144 | Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. European Journal of Clinical Pharmacology, 2011, 67, 471-476. | 0.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Protocol for Minimizing the Risk of Metachronous Adenomas of the Colorectum with Green Tea Extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutripvention of metachronous colon adenomas in the elderly population. <i>BMC Cancer</i> , 2011, 11, 360. | 1.1 | 46 |
| 146 | AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235. | 1.7 | 774 |
| 147 | Genome-wide expression profiling of human lymphoblastoid cell lines identifies <i>CHL1</i> as a putative SSRI antidepressant response biomarker. <i>Pharmacogenomics</i> , 2011, 12, 171-184. | 0.6 | 60 |
| 148 | Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. <i>Pharmacogenomics</i> , 2011, 12, 503-514. | 0.6 | 21 |
| 149 | Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide. <i>Drug Metabolism and Disposition</i> , 2011, 39, 927-932. | 1.7 | 41 |
| 150 | Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?. <i>Antiviral Therapy</i> , 2010, 15, 975-983. | 0.6 | 35 |
| 151 | A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. <i>European Journal of Neurology</i> , 2010, 17, 631-633. | 1.7 | 16 |
| 152 | Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 643-651. | 2.3 | 57 |
| 153 | Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabetics. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1106-1112. | 2.2 | 11 |
| 154 | Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. <i>Pharmacogenomics</i> , 2010, 11, 327-340. | 0.6 | 40 |
| 155 | Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. <i>European Journal of Endocrinology</i> , 2010, 163, 919-924. | 1.9 | 64 |
| 156 | Baseline Brain Perfusion and the Serotonin Transporter Promoter Polymorphism. <i>Biological Psychiatry</i> , 2010, 67, 317-322. | 0.7 | 33 |
| 157 | Impact of <i>CYP2D6*4</i> genotype on progression free survival in tamoxifen breast cancer treatment. <i>Current Medical Research and Opinion</i> , 2010, 26, 2535-2542. | 0.9 | 35 |
| 158 | Impact of <i>CYP2C8</i> and <i>2C9</i> polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. <i>Pharmacogenomics</i> , 2010, 11, 1359-1365. | 0.6 | 15 |
| 159 | The Neural Substrate of Positive Bias in Spontaneous Emotional Processing. <i>PLoS ONE</i> , 2010, 5, e15454. | 1.1 | 26 |
| 160 | Clinical Pharmacology and Anticancer Drugs. , 2010, , 11-26. | | 0 |
| 161 | Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009, 10, 1687-1695. | 0.6 | 131 |
| 162 | <i>In vivo</i> Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 433-443. | 1.1 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 19-31. | 0.8 | 204 |
| 164 | Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 54-61. | 2.3 | 44 |
| 165 | The Role of Human CYP2C8 and CYP2C9 Variants in Pioglitazone Metabolism <i>In Vitro</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 374-379. | 1.2 | 22 |
| 166 | Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. <i>Analytical Biochemistry</i> , 2009, 389, 74-76. | 1.1 | 14 |
| 167 | Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. <i>Clinica Chimica Acta</i> , 2009, 405, 49-52. | 0.5 | 78 |
| 168 | Sex-specific differences in side effects of psychotropic drugs: genes or gender?. <i>Pharmacogenomics</i> , 2009, 10, 1511-1526. | 0.6 | 81 |
| 169 | <i>CYP2D6</i> genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. <i>Pharmacogenomics</i> , 2009, 10, 685-699. | 0.6 | 34 |
| 170 | Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 387-398. | 0.8 | 8 |
| 171 | No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1033-1035. | 0.8 | 16 |
| 172 | Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 883-888. | 0.8 | 16 |
| 173 | Atypical antipsychotics in severe anorexia nervosa in children and adolescents—review and case reports. <i>European Eating Disorders Review</i> , 2008, 16, 100-108. | 2.3 | 40 |
| 174 | Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 75-82. | 2.3 | 76 |
| 175 | CYP2D6 Phenotype Prediction From Genotype: Which System Is the Best?. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 225-227. | 2.3 | 53 |
| 176 | Pharmacogenetics of Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2008, 47, 565-594. | 1.6 | 94 |
| 177 | The clinical role of genetic polymorphisms in drug-metabolizing enzymes. <i>Pharmacogenomics Journal</i> , 2008, 8, 4-15. | 0.9 | 124 |
| 178 | Pharmacogenetics-Guided Dose Modifications of Antidepressants. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 619-626. | 0.7 | 39 |
| 179 | Hepatic Nuclear Factor 1 \pm Inhibitor Ursodeoxycholic Acid Influences Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 Substrate Rosuvastatin and Bilirubin. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1453-1456. | 1.7 | 24 |
| 180 | Impact of genetic polymorphisms in <i>CYP2C8</i> and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. <i>Pharmacogenomics</i> , 2008, 9, 277-288. | 0.6 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Genetic variants in <i>FKBP5</i> affecting response to antidepressant drug treatment. <i>Pharmacogenomics</i> , 2008, 9, 841-846. | 0.6 | 101 |
| 182 | A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. <i>Pharmacogenomics Journal</i> , 2007, 7, 48-55. | 0.9 | 84 |
| 183 | Translating Pharmacogenomics: Challenges on the Road to the Clinic. <i>PLoS Medicine</i> , 2007, 4, e209. | 3.9 | 174 |
| 184 | Genetic variation at the CYP2C locus and its association with torsemide biotransformation. <i>Pharmacogenomics Journal</i> , 2007, 7, 200-211. | 0.9 | 18 |
| 185 | Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 489-494. | 1.1 | 114 |
| 186 | Characterization of a Functional Promoter Polymorphism of the Human Tryptophan Hydroxylase 2 Gene in Serotonergic Raphe Neurons. <i>Biological Psychiatry</i> , 2007, 62, 1288-1294. | 0.7 | 124 |
| 187 | Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. <i>Pharmacogenomics Journal</i> , 2007, 7, 257-265. | 0.9 | 379 |
| 188 | Response to Lithium Augmentation in Depression is Associated with the Glycogen Synthase Kinase 3-Beta δ 50T/C Single Nucleotide Polymorphism. <i>Biological Psychiatry</i> , 2007, 62, 1295-1302. | 0.7 | 96 |
| 189 | Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 270-283. | 2.3 | 220 |
| 190 | Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 699-707. | 2.3 | 40 |
| 191 | Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 657-667. | 2.3 | 106 |
| 192 | Association of CYP2D6 Genotypes and Personality Traits in Healthy Individuals. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 440-442. | 0.7 | 29 |
| 193 | AmpliChip CYP450 GeneChip [®] : A New Gene Chip That Allows Rapid and Accurate CYP2D6 Genotyping. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 673-677. | 1.0 | 72 |
| 194 | Therapeutic Drug Monitoring of Mirtazapine, Desmethylmirtazapine, 8-Hydroxymirtazapine, and Mirtazapine-N-oxide by Enantioselective HPLC With Fluorescence Detection. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 760-765. | 1.0 | 15 |
| 195 | Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 431-436. | 0.8 | 15 |
| 196 | Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. <i>European Journal of Clinical Pharmacology</i> , 2006, 63, 9-16. | 0.8 | 27 |
| 197 | Assessment Of AmpliChip CYP450 Based CYP2D6-Genotyping And Phenotype Prediction Compared To PCR-RFLP-genotyping And Phenotyping By Metoprolol Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 221. | 1.0 | 5 |
| 198 | Clinical consequences of cytochrome P450 2C9 polymorphisms. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 1-16. | 2.3 | 396 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 199 | Population variability of CYP2C9 activity in caucasians: Effects of genotype versus enzyme induction. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, P35-P35. | 2.3 | 1 |
| 200 | Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 103-106. | 1.1 | 133 |
| 201 | Pharmacogenetics-based therapeutic recommendations "ready for clinical practice?". <i>Nature Reviews Drug Discovery</i> , 2005, 4, 639-647. | 21.5 | 147 |
| 202 | Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. <i>Pharmacogenomics Journal</i> , 2005, 5, 221-225. | 0.9 | 119 |
| 203 | Epithelial Progenitors in the Normal Human Mammary Gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 49-59. | 1.0 | 141 |
| 204 | Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1859-66. | 1.7 | 46 |
| 205 | Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1209-1225. | 1.6 | 179 |
| 206 | Pharmacogenetics-Based New Therapeutic Concepts. <i>Drug Metabolism Reviews</i> , 2004, 36, 617-638. | 1.5 | 32 |
| 207 | Serotonin Syndrome With Tramadol and Citalopram. <i>American Journal of Psychiatry</i> , 2004, 161, 1129-1129. | 4.0 | 78 |
| 208 | Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. <i>Xenobiotica</i> , 2004, 34, 847-859. | 0.5 | 28 |
| 209 | Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. <i>Molecular Psychiatry</i> , 2004, 9, 442-473. | 4.1 | 661 |
| 210 | Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 165-171. | 0.8 | 66 |
| 211 | Determination of phenprocoumon, warfarin and their monohydroxylated metabolites in human plasma and urine by liquid chromatography-mass spectrometry after solid-phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 809, 217-226. | 1.2 | 34 |
| 212 | Enantio-preferential effects of the CYP2D6 genotype on bioavailability and systemic clearance of the tricyclic antidepressant trimipramine. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P19. | 2.3 | 0 |
| 213 | Effect of fluvastatin on CYP2C9 activity using warfarin as a probe. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P28. | 2.3 | 2 |
| 214 | Relationship between CYP2C9 genetic polymorphisms and effects of the loop diuretic torasemide. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P66. | 2.3 | 2 |
| 215 | On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P67. | 2.3 | 0 |
| 216 | Impact of CYP3A haplotypes on alprazolam kinetics with and without rifampicin induction. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P81. | 2.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 302-312. | 2.3 | 106 |
| 218 | polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 557-566. | 2.3 | 39 |
| 219 | Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2004, 43, 267-278. | 1.6 | 70 |
| 220 | Implications of pharmacogenetics for individualizing drug treatment and for study design. <i>Journal of Molecular Medicine</i> , 2003, 81, 154-167. | 1.7 | 52 |
| 221 | Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (âˆ™)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 186-194. | 2.3 | 109 |
| 222 | Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 448-457. | 2.3 | 20 |
| 223 | Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 31, 551-555. | 1.4 | 26 |
| 224 | Concise guide to the cytochrome P450 system: drug interaction principles for medical practice.. <i>Acta Psychiatrica Scandinavica</i> , 2003, 107, 319-319. | 2.2 | 0 |
| 225 | Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 51-61. | 1.1 | 89 |
| 226 | Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 783, 207-212. | 1.2 | 33 |
| 227 | Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 459-466. | 0.7 | 49 |
| 228 | Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 101-109. | 5.7 | 173 |
| 229 | Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 571-580. | 5.7 | 59 |
| 230 | Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 286-296. | 2.3 | 183 |
| 231 | Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 62-75. | 2.3 | 116 |
| 232 | The impact of the polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 438-452. | 2.3 | 173 |
| 233 | CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:â€”a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 173-192. | 2.2 | 367 |